Indication
In combination with other pulmonary arterial hypertension (PAH) therapies, is indicated for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity.
Medicine details
- Medicine name:
- sotatercept (Winrevair)
- SMC ID:
- SMC2923
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Resubmission
- Publication due date:
- TBC
- SMC meeting date:
- TBC